Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615001106527
Ethics application status
Approved
Date submitted
15/09/2015
Date registered
21/10/2015
Date last updated
8/04/2021
Date data sharing statement initially provided
11/01/2019
Date results provided
11/01/2019
Type of registration
Prospectively registered

Titles & IDs
Public title
Chemotherapy-induced alopecia (CIA) in breast cancer patients: effectiveness of two temperature levels of scalp cooling on reducing rates of CIA.
Scientific title
Incidence of chemotherapy-induced alopecia (CIA) in breast cancer patients": effectiveness of two temperature levels of scalp cooling on reducing incidence of CIA
Secondary ID [1] 287475 0
BCRC113
Universal Trial Number (UTN)
Trial acronym
CIA-study
Linked study record

Health condition
Health condition(s) or problem(s) studied:
chemotherapy-induced alopecia 296217 0
breast cancer 296288 0
Condition category
Condition code
Cancer 296490 296490 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
scalp-cooling treatment:patient wears a cap which is connected to a refrigerated cooling system which pumps liquid coolant through the cap to keep the scalp cool and blood vessels constricted to minimise chemotherapy delivery to hair follicles. The TGA-approved cap will be fitted to patients on day 1 of each chemotherapy cycle at one of two temperature settings (3 degrees vs 5 degrees Celsius) 30 min prior, during and 90min after their chemotherapy treatment for the duration of their planned chemotherapy. Scalp cooling start/stop time, chemotherapy start/stop time as well as duration of scalp cooling interruption, if applicable, will be recorded.
Intervention code [1] 292858 0
Treatment: Devices
Comparator / control treatment
Historical data (viz published adjuvant chemotherapy trials evaluating contemporary chemotherapy regimens from early 2000 to current)
Control group
Historical

Outcomes
Primary outcome [1] 296116 0
incidence of patient reported minimal CIA (Dean's score 1/2 OR WHO grade 1/2) after completion of planned chemotherapy in this clinical setting compared to the population overall
Timepoint [1] 296116 0
End of chemotherapy
Secondary outcome [1] 317544 0
comparison of rate of minimal CIA ( patient-reported on Dean's scale for Hair loss and WHO Scale for Hair Loss) at the 2 temperature settings as per protocol
Timepoint [1] 317544 0
End of chemotherapy
Secondary outcome [2] 317545 0
Rate of compliance with scalp cooling as determined in the protocol: patient's adherence to scalp cooling duration at each cycle, and patient's adherence to scalp cooling temperature setting. Temperature settings and scalp cooling times as well as chemotherapy treatment times will be collected.
Timepoint [2] 317545 0
per cycle and overall for planned number of chemotherapy cycles
Secondary outcome [3] 317546 0
Composite outcome: frequency and severity of scalp-cooling adverse events. Known reported side-effects are feeling of cold, headache and light-headedness. At each treatment, the patient will be asked for any AEs/SAEs by study site staff who will document and report those AEs in the CRF and grade them according to CTCAE.
Timepoint [3] 317546 0
throughout study, at the start of each scalp cooling treatment
Secondary outcome [4] 317547 0
incidence of scalp metastasis as reported by patients (phone contact) or from review of medical records (routine standard of care visit)
Timepoint [4] 317547 0
yearly for 10 years since start of chemotherapy

Eligibility
Key inclusion criteria
- histologically confirmed invasive breast cancer
- suitable to receive one of the approved chemotherapy regiments, defined in the protocol, in the neo/adjuvant or metastatic setting
- minimum understanding of English language to complete quality of life questionnaire
- willingness to be followed for 10 years
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
- history of malignant primary brain tumour
- history of scalp or brain metastasis
- recommended chemotherapy given on weekly schedule
- patient suffering from cold sensitivity, cold agglutinin disease, cryoglobulinemia, cryofibrogenemia or cold traumatic dystrophy
- prior chemotherapy for any reason
- allergy to silicon
- concurrent treatment affecting hair growth

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Within each treatment cohort, eligible patients will be randomised to one of two scalp cooling treatment arms on a 1:1 ratio.
Randomisation will be allocated by selected staff who do not have direct patient contact during the study. Allocation is concealed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Patients will be stratified according to treatment regimen recommended. There will be 3 treatment cohorts and within each cohort eligible patients will be randomised to one of two scalp cooling treatment arms on a 1:1 ratio.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
To detect a difference with 80% of power at a one-sided significant level of 0.025 (ower from 0.05 as Bonferroni correction applied to enable multiple groups comparisons), stratifying for treatment cohorts, a sample of 20 per cohort is required (assuming 20% dropout rate)

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
23/12/2015
Actual
30/12/2015
Date of last participant enrolment
Anticipated
Actual
10/02/2017
Date of last data collection
Anticipated
13/11/2025
Actual
Sample size
Target
60
Accrual to date
Final
63
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 4349 0
Breast Cancer Research Centre - Western Australia - Perth
Recruitment postcode(s) [1] 10575 0
6000 - Perth

Funding & Sponsors
Funding source category [1] 292053 0
Charities/Societies/Foundations
Name [1] 292053 0
Breast Cancer Research Centre - WA
Country [1] 292053 0
Australia
Primary sponsor type
Charities/Societies/Foundations
Name
Breast Cancer Research Centre of Western Australia
Address
Hollywood Consulting Centre
Suite 407, 4th floor
91 Monash Avenue
Nedlands WA 6009
Country
Australia
Secondary sponsor category [1] 290726 0
None
Name [1] 290726 0
Address [1] 290726 0
Country [1] 290726 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 293535 0
Bellberry
Ethics committee address [1] 293535 0
Ethics committee country [1] 293535 0
Australia
Date submitted for ethics approval [1] 293535 0
14/10/2015
Approval date [1] 293535 0
30/11/2015
Ethics approval number [1] 293535 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 60350 0
Prof Arlene Chan
Address 60350 0
Breast Cancer Research Centre,-WA, Suite 407, Hollywood Consulting Centre, 91 Monash Avenue, Nedlands, 6009 WA
Country 60350 0
Australia
Phone 60350 0
+ 61 8 9481 4522
Fax 60350 0
Email 60350 0
[email protected]
Contact person for public queries
Name 60351 0
Jeannette Devoto
Address 60351 0
Breast Cancer Research Centre,-WA, Suite 407, Hollywood Consulting Centre, 91 Monash Avenue, Nedlands, 6009 WA
Country 60351 0
Australia
Phone 60351 0
+61 8 6500 5556
Fax 60351 0
Email 60351 0
[email protected]
Contact person for scientific queries
Name 60352 0
Jeannette Devoto
Address 60352 0
Breast Cancer Research Centre,-WA, Suite 407, Hollywood Consulting Centre, 91 Monash Avenue, Nedlands, 6009 WA
Country 60352 0
Australia
Phone 60352 0
+61 8 6500 5556
Fax 60352 0
Email 60352 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
Data will only be shared amongst participating investigators as pertains to the study endpoints and specified analyses
When will data be available (start and end dates)?
At time of data clean and first data analysis and up until time of final publication
Available to whom?
Participating investigators
Available for what types of analyses?
Analyses as planned per protocol, or as exploratory analyses based on study's findings which may serve as rationale for further clinical research evaluation
How or where can data be obtained?
Data fields from primary study database will be shared as de-identified records in Excel spreadsheet.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseEfficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens.2018https://dx.doi.org/10.1016/j.breast.2018.07.006
N.B. These documents automatically identified may not have been verified by the study sponsor.